Navigation Links
InterMune to Release Second Quarter Financial Results on August 6
Date:7/29/2009

BRISBANE, Calif., July 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release second quarter 2009 financial results on Thursday, August 6, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 22196018. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 22196018.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research prog
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24/PRNewswire/--Twomoreprestigiousuniversitieshave...oardandcareerssiteforlifescienceprofessionals. ,...fthejobboard,joining28othermajorlifesciencetrainin...ter.com ,isonlyforpost-graduatesinthelifesciences....Internet,BioCareerCenteristheonlyonethatserveslife...
(Date:11/24/2009)...swire-FirstCall/--Sigma-AldrichCorporation(Nasdaq:...uesday,December1stat1:45PMGMTinLondon,7:45AMUS/CST...ertheInternetavailableat http://inve s tor.sig ...contoaccessthisfile. ,, AboutSigma-Aldrich: ...ycompany.Itschemicalandbiochemicalproductsandkitsa...
(Date:11/24/2009)...swire-Asia/--NODPharmaceuticalsInc.announced,theUS...applicationfor,itsnano-particleoraldeliveryorNODte...proachtoincorporatepeptidesor,proteinsintobio-adhe...rwiseadministeredasinjections.NODtechnologyisaplat...rdrugssuchasinsulin,interferon,growthhormone,exen...
(Date:11/24/2009)...wire/--BlueMarbleEnergyCorp.announcedtodaythatthec...wererecentlyawarded$2millionbyWashingtonState,sCom...publicpartnershiptoconstructthestate,sfirstspecial..."Thisinvestmentwillsignificantlyspeedthedevelopmen...ounty,"saidBlueMarbleEnergyCEOKellyOgilvie."Weareg...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...ific (NYSE: BSX ) today announced special items ...uarter. The Company plans to release its first qu...ompany disclosed last month, the Court of Appeals ...s decision that Johnson & Johnson,s (J&J) ...e Boston Scientific,s patent and that the patent i...
...gnostics,Incorporated (NYSE: DGX ) today announc...osed federal government investigation related to c...anufacturing subsidiary closed,voluntarily in 2006... since,its investigation began in 2004. , Ques...civil investigation.,While the company disagrees w...
...announced today that it,has completed the formatio...ment its existing group of Senior Advisers. NexBi... of DAS181 (Fludase(R)), an investigational drug,c...Bio throughout the clinical,development of this no...ced,product development to address the threat of a...
Other Biology Technology:Boston Scientific Announces First Quarter Special Items 2Boston Scientific Announces First Quarter Special Items 3Boston Scientific Announces First Quarter Special Items 4Boston Scientific Announces First Quarter Special Items 5Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 3NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 4
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Prostate cancer gives a new outlook on life 58853 1Prostate cancer gives a new outlook on life 58853 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 1University of Washington receives 2425 million to create Northwest Genomics Center 10256 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 3University of Washington receives 2425 million to create Northwest Genomics Center 10256 4Focused Radiation Protects Tumor Patients Brain Function 58850 1Focused Radiation Protects Tumor Patients Brain Function 58850 2
... in response to higher global temperatures may be ...count plants, ability to adjust to changing condit...onal Laboratory. , In a Perspectives paper publish...tes ORNL findings suggesting that about 9 percent ... the acclimation of plants included in the model. ...
...bage-eating moth may one day provide a safer, targ...y, researchers say. , , They compared the abilit... transposons, to insert themselves into a cell,s D...e cell resistant to damage from radiation therapy....o 10 times better than the other circular pieces o...
...nia, Los Angeles have defined conditions associate...n almost a third of breast cancer survivors, accor...ncer Research. , The key to their fatigue stems ...hese studies identify a biological basis for persi...ted by inflammation," said Michael Irwin, M.D., di...
Other Biology News:Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Inflammation markers identify fatigue in breast cancer survivors 2
EDTA Solution (pH 8.0) (0.5 M) from BioVision
Rat Anti-Mouse Limitin Monoclonal Antibody, Unconjugated, Clone 183727 from R&D Systems
Normal Human Serum from CHEMICON
Human HGF, Unconjugated from R&D Systems
Biology Products: